Flagellin-Induced Antiviral Activity
鞭毛蛋白诱导的抗病毒活性
基本信息
- 批准号:8655677
- 负责人:
- 金额:$ 22.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-12-12 至 2015-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAntiviral AgentsB-LymphocytesBiochemicalBiological ModelsBone MarrowCell LineCellsChronicCoculture TechniquesDendritic CellsDevelopmentDiarrheaEngineeringEpithelial CellsFlagellinGeneticGoalsHealthHumanitiesImmuneInfectionInfectious AgentInterferon Type IInterferon Type IIInterferonsIntestinesLeftLeukocytesMediatingMediator of activation proteinModalityModelingMolecularMusNatural ImmunityOutcomePathway interactionsPlaguePolyomavirusPreventionProcessProductionRelative (related person)ResistanceRoleRotavirusRotavirus InfectionsSeriesSmall IntestinesSourceSystemT-LymphocyteTherapeuticToll-Like Receptor 5ViralVirusVirus DiseasesWorkadaptive immunitycell typecombatcytokineimmune activationin vivoinfluenzavirusnovelnovel strategiespreventprotective effectreceptorresponseweapons
项目摘要
Viral infections cause and/or promote many of humanity's most intractable health problems. Most viral
infections can neither be prevented nor cured thus leaving a great need for novel strategies to combat
these infectious agents. This proposal seeks to help fill this chasm by investigating our startling recent
discovery of the existence of a novel potent innate immune antiviral mechanism. Specifically, using
murine rotavirus (RV) infection as a model of an acute diarrhea---inducing infection in young mice and a
chronic infection in immune---deficient mice, we recently made the unexpected observation that systemic
administration of bacterial flagellin could prevent or eliminate ongoing rotavirus infection. Flagellin's
antiviral action was independent of adaptive immunity and interferon (type I and II) while requiring
hemopoietic cell expression of both known flagellin receptors, toll---like receptor 5 (TLR5) and Nod---like
receptor C4 (NLRC4). Flagellin's blockade of rotavirus infection may be utilizing pathways that normally
mediate bacterial---viral competition/crosstalk or prove to be a purely engineered approach that does not
mimic a naturally occurring in vivo process. Regardless, that exogenously administered flagellin results
in rapid cure of chronic viral infections that would not otherwise be resolved by immune compromised
hosts suggests the possibility that this mechanism, if understood and harnessed, might provide new
weapons against some of the numerous viruses that continue to plague humanity. Thus, while
development of new modalities to treat rotavirus infection is one potential outcome of this project, the
primary overall goal of this proposal is to define the mechanism underlying flagellin's antiviral
action so it can be harnessed to develop novel strategies to treat a variety of viral infections. We
will employ a series of inter---related genetic, immunological and biochemical approaches to define the cell
type(s), soluble mediator(s) that cure and prevent RV infection and decipher their mode of action.
病毒感染导致和/或促进人类许多最棘手的健康问题。 大多数病毒
感染既不能预防也不能治愈,因此非常需要新的战略来对抗
这些传染源。 这项建议旨在通过调查我们最近令人震惊的
发现存在一种新的有效的先天免疫抗病毒机制。 具体而言,使用
小鼠轮状病毒(RV)感染作为幼鼠急性腹泻诱导感染的模型,
免疫缺陷小鼠的慢性感染,我们最近意外地观察到,
施用细菌鞭毛蛋白可以预防或消除正在进行的轮状病毒感染。 弗拉格林氏
抗病毒作用不依赖于获得性免疫和干扰素(I型和II型),
已知鞭毛蛋白受体Toll样受体5(TLR 5)和Nod样受体
受体C4(NLRC 4)。 鞭毛蛋白对轮状病毒感染的阻断作用可能是利用了通常
介导细菌-病毒竞争/串扰或证明是一种纯粹的工程方法,
模拟自然发生的体内过程。 无论如何,外源性鞭毛蛋白导致
在慢性病毒感染的快速治愈中,
主持人认为,如果理解和利用这种机制,
这些武器对付继续困扰人类的众多病毒中的一些。因此,虽然
开发治疗轮状病毒感染的新方法是该项目的一个潜在成果,
该提案的主要总体目标是确定鞭毛蛋白抗病毒的潜在机制
因此,它可以被用来开发新的策略来治疗各种病毒感染。 我们
将采用一系列相互关联的遗传学、免疫学和生物化学方法来定义细胞
类型,治疗和预防RV感染的可溶性介质,并解释其作用模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew T Gewirtz其他文献
Andrew T Gewirtz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew T Gewirtz', 18)}}的其他基金
Intestinal microbiota-mediated rotavirus vaccine failure
肠道微生物介导的轮状病毒疫苗失败
- 批准号:
10586698 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
Intestinal microbiota-mediated rotavirus vaccine failure
肠道微生物介导的轮状病毒疫苗失败
- 批准号:
10707184 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
Intestinal M Cells and Secretory IgA Response to Defined Gut Microbiota
肠道 M 细胞和分泌型 IgA 对特定肠道微生物群的反应
- 批准号:
8684523 - 财政年份:2014
- 资助金额:
$ 22.2万 - 项目类别:
Intestinal M Cells and Secretory IgA Response to Defined Gut Microbiota
肠道 M 细胞和分泌型 IgA 对特定肠道微生物群的反应
- 批准号:
8793099 - 财政年份:2014
- 资助金额:
$ 22.2万 - 项目类别:
Deconstructing Inflammation and Altered Microbiota in Metabolic Syndrome
解构代谢综合征中的炎症和改变的微生物群
- 批准号:
9194750 - 财政年份:2013
- 资助金额:
$ 22.2万 - 项目类别:
Deconstructing Inflammation and Altered Microbiota in Metabolic Syndrome
解构代谢综合征中的炎症和改变的微生物群
- 批准号:
8842835 - 财政年份:2013
- 资助金额:
$ 22.2万 - 项目类别:
Deconstructing Inflammation and Altered Microbiota In Metabolic Syndrome
解构代谢综合征中的炎症和改变的微生物群
- 批准号:
8891414 - 财政年份:2013
- 资助金额:
$ 22.2万 - 项目类别:
Deconstructing Inflammation and Altered Microbiota In Metabolic Syndrome
解构代谢综合征中的炎症和改变的微生物群
- 批准号:
8609941 - 财政年份:2013
- 资助金额:
$ 22.2万 - 项目类别:
Deconstructing Inflammation and Altered Microbiota in Metabolic Syndrome
解构代谢综合征中的炎症和改变的微生物群
- 批准号:
9323386 - 财政年份:2013
- 资助金额:
$ 22.2万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 22.2万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 22.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 22.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 22.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 22.2万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




